Literature DB >> 11560782

Structure-activity of inhibition of HIV-1 integrase and virus replication by G-quartet oligonucleotides.

N Jing1, C Marchand, Y Guan, J Liu, L Pallansch, C Lackman-Smith, E De Clercq, Y Pommier.   

Abstract

As novel anti-HIV agents, the G-tetrad-forming oligonucleotides have been explored for their structure-activity relations with regard to inhibition of integrase (IN) (N. Jing, Expert Opin. Investig. Drugs (2000) 9, 1777-1785). We have now developed two families of G-quartet oligonucleotides: T40217-T40222, with potential formation of a tail-to-tail G-quartet dimer, and T40224-T40227, with phosphorothioate (PT) linkages in the guanine loops. The results obtained from biophysical measurements and the assays of the inhibition of HIV-1 IN and virus replication demonstrated that an increase in the length of the G-quartet structure from a monomer (15A) to a tail-to-tail dimer (47A) does not distinctly disrupt the inhibition of HIV-1 IN activity or the inhibition of HIV-1 replication in cell cultures. G-quartet oligonucleotides were observed to induce molecular aggregation of HIV-1 IN and interrupt the binding of viral DNA to HIV-1 IN. Also, PT substitutions did not confer any advantages compared with the regular phosphodiesters for the inhibition of HIV-1 replication by intramolecular G-quartets. The G-quartet motif is the primary requirement for the remarkable nuclease resistance and pronounced biological efficacy of these oligonucleotides.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11560782     DOI: 10.1089/104454901316976136

Source DB:  PubMed          Journal:  DNA Cell Biol        ISSN: 1044-5498            Impact factor:   3.311


  7 in total

Review 1.  Aptamers in HIV research diagnosis and therapy.

Authors:  Jyoti Bala; Srinivasan Chinnapaiyan; Rajib Kumar Dutta; Hoshang Unwalla
Journal:  RNA Biol       Date:  2018-02-12       Impact factor: 4.652

2.  Kinetic ESI-MS Studies of Potent Anti-HIV Aptamers Based on the G-Quadruplex Forming Sequence d(TGGGAG).

Authors:  Valeria Romanucci; Adrien Marchand; Oscar Mendoza; Daniele D'Alonzo; Armando Zarrelli; Valérie Gabelica; Giovanni Di Fabio
Journal:  ACS Med Chem Lett       Date:  2016-01-26       Impact factor: 4.345

3.  Azido-containing diketo acid derivatives inhibit human immunodeficiency virus type 1 integrase in vivo and influence the frequency of deletions at two-long-terminal-repeat-circle junctions.

Authors:  Evguenia S Svarovskaia; Rebekah Barr; Xuechun Zhang; Godwin C G Pais; Christophe Marchand; Yves Pommier; Terrence R Burke; Vinay K Pathak
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

Review 4.  HIV-1 IN inhibitors: 2010 update and perspectives.

Authors:  Christophe Marchand; Kasthuraiah Maddali; Mathieu Métifiot; Yves Pommier
Journal:  Curr Top Med Chem       Date:  2009       Impact factor: 3.295

5.  Resistance to integrase inhibitors.

Authors:  Mathieu Métifiot; Christophe Marchand; Kasthuraiah Maddali; Yves Pommier
Journal:  Viruses       Date:  2010-06-25       Impact factor: 5.048

Review 6.  Targeting STAT3 in Cancer with Nucleotide Therapeutics.

Authors:  Yue-Ting K Lau; Malini Ramaiyer; Daniel E Johnson; Jennifer R Grandis
Journal:  Cancers (Basel)       Date:  2019-10-29       Impact factor: 6.639

7.  A Chimeric DNA/RNA Antiparallel Quadruplex with Improved Stability.

Authors:  Elaina P Boyle; Levan Lomidze; Karin Musier-Forsyth; Besik Kankia
Journal:  ChemistryOpen       Date:  2022-02       Impact factor: 2.630

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.